Skip to main
SLDB
SLDB logo

Solid Biosciences (SLDB) Stock Forecast & Price Target

Solid Biosciences (SLDB) Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 33%
Buy 52%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Solid Biosciences Inc is focused on developing innovative gene therapy treatments for Duchenne muscular dystrophy (DMD), with promising pipeline products like SGT-003 projected to generate risk-adjusted revenues of $1 billion by 2033, up from $90 million in 2028. Clinical data indicates significant improvements in cardiac function and muscle integrity, with an 8% increase in left ventricular ejection fraction (LVEF) in patients, suggesting strong potential benefits for both ambulatory and non-ambulatory DMD patients. Additionally, the company’s strategic emphasis on new metrics for evaluating treatment efficacy may enhance the addressable market and strengthen its position within the neuromuscular disease space.

Bears say

Solid Biosciences Inc. faces significant financial risks primarily due to its reliance on the successful regulatory approval of its lead product candidate, SGT-003, for the treatment of Duchenne muscular dystrophy. The company could experience substantial downward revisions in its projections and overall valuation if regulatory approvals are not granted or if clinical trials encounter unforeseen safety issues, such as systemic toxicity. Additionally, potential constraints on manufacturing capacity for SGT-003 could materially impact sales, further exacerbating the company’s financial challenges in a highly competitive biotech environment.

Solid Biosciences (SLDB) has been analyzed by 21 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 52% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Solid Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Solid Biosciences (SLDB) Forecast

Analysts have given Solid Biosciences (SLDB) a Buy based on their latest research and market trends.

According to 21 analysts, Solid Biosciences (SLDB) has a Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Solid Biosciences (SLDB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.